Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "pharmaceuticals"

1579 News Found

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


SMS Pharmaceuticals posts Q4FY21 consolidated PAT of Rs. 22.21 Cr
News | May 29, 2021

SMS Pharmaceuticals posts Q4FY21 consolidated PAT of Rs. 22.21 Cr

It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021


Reports on GSK Pharmaceuticals by ICICI Securities
News | April 03, 2021

Reports on GSK Pharmaceuticals by ICICI Securities

GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn


From farm to pharmaceuticals: Traditional medicine in a phytopharma avatar
News | March 10, 2021

From farm to pharmaceuticals: Traditional medicine in a phytopharma avatar

Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.


India approves PLI scheme for pharmaceuticals
News | February 26, 2021

India approves PLI scheme for pharmaceuticals

Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.


SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr
News | February 11, 2021

SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr

The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.


J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr
News | February 11, 2021

J B Chemicals & Pharmaceuticals Q3FY 21 consolidated PAT up at Rs. 151.66 Cr

The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.


GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr
News | February 06, 2021

GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr

The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.


FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
Drug Approval | November 21, 2025

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options


EMA launches streamlined process to fast-track critical medicines, vaccines
News | November 21, 2025

EMA launches streamlined process to fast-track critical medicines, vaccines

The move is expected to be crucial during health crises